First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, James W. Mier et al.|Cancer Discovery|2017Cited by 418
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyLeila Khoja, Anthony M. Joshua, Eshetu G. Atenafu et al.|Annals of Oncology|2019Cited by 282
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanomaSapna P. Patel, Craig L. Slingluff|Journal for ImmunoTherapy of Cancer|2021Cited by 61
The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanomaDai Ogata, Rodabe N. Amaria, Lauren E. Haydu et al.|Cancer Medicine|2021Cited by 31